Skip to content

A clinical study on Bronchial Asthma in children

"A comparative clinical evaluation of chitraka haritaki avaleha and bharangyadi avaleha in the management of tamaka shwasa(bronchial asthama) - TSCHABA

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/05/006971
Enrollment
30
Registered
2016-05-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients having signs and symptoms of bronchial asthma

Interventions

Intervention1: In group A Chitraka haritaki avaleha, reference Bhaisajya ratnawali,nasarogadhikar slok no.25-27: duration of the treatment 6 weeks and follwup 8 weeks.drug orally administreted and dos

Sponsors

Director IPGT RA GAU JAMNAGAR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of 2-10 years of age of either sex. Diagnosed cases of Tamaka Shwasa with atleast 2 episodes of asthma symptoms during the previous year. Patients on other drug therapy will be included only after completion of wash out period of 3 weeks.

Exclusion criteria

Exclusion criteria: Children of age below 2 years and above 10 years. Evidence of active Concomitants Pulmonary Disease other than asthma. Evidence of requirement of intubations for asthma, or had been hospitalized for asthma within one month before.Had Unresolved Sinus Disease or an unresolved upper or lower respiratory tract infection within 2 weeks. Patients on active Corticosteroid Therapy Or More Than 4 short courses of oral corticosteroids within the year preceding the screening visit,or any oral corticosteroids in the preceding 4 weeks.Use of Astemizole,Nedocromil, Cromolyn,long acting beta agonists,Ketotifen,or Theophylline within 2 weeks before. Concomitant severe de-compensated systemic disease(cardiovascular,renal,hepatic,endocrine,hematological,neurological,immunological)

Design outcomes

Primary

MeasureTime frame
Relieve in the sign and symptoms of shwasa Roga or Bronchial AsthmaTimepoint: 6 weeks

Secondary

MeasureTime frame
To prevent the recurrence of attacks of breathlessness To increase the immunity against allergensTimepoint: 6 weeks

Countries

India

Contacts

Public ContactDr V K kori

IPGT & RA JAMNAGAR

drkspatel2007@yahoo.co.in9427574566

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026